ZONKAYRAS Trademark

Trademark Overview


On Thursday, December 7, 2023, a trademark application was filed for ZONKAYRAS with the United States Patent and Trademark Office. The USPTO has given the ZONKAYRAS trademark a serial number of 98302890. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, June 20, 2024. This trademark is owned by Eli Lilly and Company. The ZONKAYRAS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative co...
zonkayras

General Information


Serial Number98302890
Word MarkZONKAYRAS
Filing DateThursday, December 7, 2023
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateThursday, June 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 23, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
Translation of Words in MarkThe wording "ZONKAYRAS" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 7, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Thursday, December 7, 2023NEW APPLICATION ENTERED
Monday, March 4, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 20, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, June 20, 2024ASSIGNED TO EXAMINER
Wednesday, July 3, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED